http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103393719-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_553f1f14a621c8f40d9e6dc5cece0670
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2013-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b18cd521c78529a8436f7698004b2120
publicationDate 2014-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103393719-B
titleOfInvention Production method of arsenic trioxide oral liquid
abstract Belonging to the technical field of medicines, the invention particularly relates to a production method of an arsenic trioxide oral liquid. The production method of the arsenic trioxide oral liquid provided in the invention comprises the steps of: (1) weighing arsenic trioxide, then putting it in an sterile container, adding water for injection and sodium hydroxide, conducting heating and stirring till dissolution, thus obtaining a solution; and (2) adding a corrective agent and an aseptic into the solution obtained in step (1), performing stirring for dissolution, then adding a pH regulator to regulate the pH to 3.0-7.0, and then adding water for injection to a needed amount, carrying filtering by a microfiltration membrane, sealing the solution in a brown bottle, and conducting sterilization, thus obtaining the arsenic trioxide oral liquid. The arsenic trioxide oral liquid produced by the method provided in the invention can be applicable to leukemia and liver cancer, is suitable for different types of patients, and has stable quality after long term storage.
priorityDate 2013-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425172137
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453808416
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1118
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID545
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431646646
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557108
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412584819
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14798
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493487
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407698410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409060395
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID311
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551217
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66679818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID517055
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419482173
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474445
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID518740
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450130362
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID442089
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13351310

Total number of triples: 47.